WO1995024907A3 - Compositions pharmaceutiques contenant du sulfate de laminarine - Google Patents

Compositions pharmaceutiques contenant du sulfate de laminarine Download PDF

Info

Publication number
WO1995024907A3
WO1995024907A3 PCT/GB1995/000515 GB9500515W WO9524907A3 WO 1995024907 A3 WO1995024907 A3 WO 1995024907A3 GB 9500515 W GB9500515 W GB 9500515W WO 9524907 A3 WO9524907 A3 WO 9524907A3
Authority
WO
WIPO (PCT)
Prior art keywords
sulfate
laminarin sulfate
inhibition
sodium
pharmaceutical composition
Prior art date
Application number
PCT/GB1995/000515
Other languages
English (en)
Other versions
WO1995024907A2 (fr
Inventor
Israel Vlodavsky
Hua-Quan Miao
Original Assignee
Hadasit Med Res Service
Whalley Kevin
Israel Vlodavsky
Miao Hua Quan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Whalley Kevin, Israel Vlodavsky, Miao Hua Quan filed Critical Hadasit Med Res Service
Priority to AU18567/95A priority Critical patent/AU1856795A/en
Publication of WO1995024907A2 publication Critical patent/WO1995024907A2/fr
Publication of WO1995024907A3 publication Critical patent/WO1995024907A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne une composition pharmaceutique contenant du sulfate de laminarine de sodium servant à imiter l'activité de l'héparine, et utilisé à des fins thérapeutiques à la place de l'héparine dans la prévention de la resténose par inhibition de la prolifération des cellules des muscles lisses vasculaires, dans l'accélération de la cicatrisation par activation de la libération de facteurs de croissance actifs emmagasinés dans la matrice extracellulaire, ainsi que dans l'inhibition de la métastase de cellules tumorales par inhibition de l'activité d'héparanase. Cette composition pharmaceutique contient une quantité pharmaceutiquement efficace de sulfate de laminarine de sodium combinée à un véhicule pharmaceutiquement acceptable, le rapport molaire entre les groupes de sulfate et les unités de monosaccharide dans ledit sulfate de laminarine étant d'au moins 1:1.
PCT/GB1995/000515 1994-03-13 1995-03-10 Compositions pharmaceutiques contenant du sulfate de laminarine WO1995024907A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU18567/95A AU1856795A (en) 1994-03-13 1995-03-10 Pharmaceutical compositions containing laminarin sulfate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10895194A IL108951A0 (en) 1994-03-13 1994-03-13 Pharmaceutical compositions containing polysulfated polysaccharides
IL108951 1994-03-13

Publications (2)

Publication Number Publication Date
WO1995024907A2 WO1995024907A2 (fr) 1995-09-21
WO1995024907A3 true WO1995024907A3 (fr) 1995-11-09

Family

ID=11065921

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1995/000515 WO1995024907A2 (fr) 1994-03-13 1995-03-10 Compositions pharmaceutiques contenant du sulfate de laminarine

Country Status (3)

Country Link
AU (1) AU1856795A (fr)
IL (1) IL108951A0 (fr)
WO (1) WO1995024907A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO104496A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
AU4808997A (en) 1996-09-30 1998-04-24 Brigham And Women's Hospital Methods and compounds for treatment of abnormal uterine bleeding
FR2816213B1 (fr) 2000-11-03 2005-04-22 Goemar Lab Sa Medicament anti-inflammatoire et cicatrisant
GB0112649D0 (en) * 2001-05-24 2001-07-18 Isis Innovation Macrophage receptor
US6660722B2 (en) * 2001-11-30 2003-12-09 Laboratoires Goemar S.A. Therapeutical treatments
FR2900577B1 (fr) 2006-05-04 2008-09-12 Goemar Lab Sa Nouveaux medicaments pour les traitements contre le virus de l'herpes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
B. JOLLES ET AL.: "ffects of sulphated degraded laminarin on experimental tumour growth", BR. J. CANCER, vol. 17, pages 109 - 115 *
D.H.PAPER ET AL.: "Effects of laminarin sulphates on transforming growth factor and basic fibroplast growth factor", PLANTA. MED., vol. 58, no. sup1, pages A585 - A586 *
DAVID HASDAI ET AL.: "The non-antithrombotic therapeutic potential of heparin and related haparinoids in cardiovascular diseases", CORONARY ARTERY DISEASE, vol. 5, no. 1, pages 81 - 91 *
MASAKI KOBAYASHI ET AL.: "Inhibition of blood-borne pulmonary metastasis by sulfated polysaccharides", TOKUSHIMA J. EXP. MED., vol. 26, no. 1-2, pages 41 - 51 *
R.PAUL ET AL.: "Inhibition of vascular smooth muscle cell proliferation in culture by pentosan polysulphate and related compounds", THROMB. RES., vol. 46, no. 6, pages 793 - 801 *
S.ALBAN ET AL.: "Synthesis of laminarin sulfates with anticagulant activity", ARZNEIMITTELFORSCHUNG, vol. 42, no. 8, pages 1005 - 1008 *

Also Published As

Publication number Publication date
WO1995024907A2 (fr) 1995-09-21
AU1856795A (en) 1995-10-03
IL108951A0 (en) 1994-06-24

Similar Documents

Publication Publication Date Title
EP1447098A3 (fr) Inhibiteurs therapeutiques des cellules vasculaires
CA2145093A1 (fr) Inhibiteur therapeutique des cellules musculaires lisses
UA72882C2 (uk) Спосіб лікування нестабільності чи надактивності сечового міхура, фармацевтична композиція з регульованим вивільненням та використання толтеродину
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
MY132705A (en) Novel compounds with analgesic effect
NZ321738A (en) 3-pyridine-2-heterocyclic substituted imidazoles and medicaments having anti-cancer and cytokine inhibitory activity
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
EP2295063A8 (fr) Compositions et leur utilisation pour le traitement de maladies mitochondriales
ES8402155A1 (es) Un metodo para producir formas posologicas unitarias solidas que al administrarse siguen una pauta de liberacion regular y prolongada.
AU5090796A (en) Use of dextromethorphan or dextrorphan for the treatment of urinary incontinence
GEP20043334B (en) Hydrogel-Driven Drug Dosage Form
MX9307509A (es) Metodo y preparacion farmaceutica para reducir la actividad de las celulas.
CA2125662A1 (fr) Systeme a administration transdermique contenant de l'acide acetylsalicylique pour le traitement de la thrombose et la prophylaxie du cancer
WO2001030802A3 (fr) Traitements therapeutiques pour des deficiences en cellules sanguines
GEP20043162B (en) Derivatives of Isosorbid Mononitrate, Utilization as Vasodilator Agents with Reduced Tolerance
EP0137543A3 (en) Pharmaceutical composition for the therapy of peripheral arteriopathies
EP0754457A4 (fr) Agent anti-obesite
EP1310256A3 (fr) Utilisation de la prostaglandine A ou de ses dérivés pour le traitement du psoriasis
CA2139385A1 (fr) Produits renfermant une proteine liante de g-csf et de tnf
WO1995024907A3 (fr) Compositions pharmaceutiques contenant du sulfate de laminarine
MY124465A (en) Reduction of infarct volume using citicoline
MX9805141A (es) Uso de inhibidores del intercambiador celular na+/h+ (nhe) para la preparacion de un farmaco para estimular la respiracion.
DE69519385D1 (de) Chinazolinon-arzneimittel sowie deren verwendung
EP1304108A3 (fr) Compositions pour traiter l'arythmie et procédés de traitement

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase